|Articles|October 1, 2012

Warning on SimplyThick now includes infants of any age

The US Food and Drug Administration (FDA) cautions that SimplyThick, a brand of thickening agent added to breast milk or formula for premature babies, has been linked to necrotizing enterocolitis (NEC) in a full-term infant.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

ByDruhan Howell, MD

November 25th 2025

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

ByJoshua Fitch, Senior Editor

November 25th 2025

FDA approves first gene replacement therapy (Itvisma) for patients 2 years and older with spinal muscular atrophy

ByMorgan Ebert, Managing Editor

November 25th 2025

Jonathan Flyer, MD, highlights the LEAD initiative to increase pediatric lipid screenings

ByJonathan N. Flyer, MD

November 24th 2025

Can you diagnose this corneal lesion in an 8-year-old girl?

ByJenna Scanlon, DO,Melissa Mondello, MD,Jennifer Haile, MD

November 24th 2025

Latest CME

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Warning on SimplyThick now includes infants of any age

Newsletter

Related Content

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

FDA approves first gene replacement therapy (Itvisma) for patients 2 years and older with spinal muscular atrophy

Jonathan Flyer, MD, highlights the LEAD initiative to increase pediatric lipid screenings

Can you diagnose this corneal lesion in an 8-year-old girl?

Latest CME

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

FDA approves first gene replacement therapy (Itvisma) for patients 2 years and older with spinal muscular atrophy

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

Ruxolitinib Efficacy and Safety in Pediatric AD

Jonathan Flyer, MD, highlights the LEAD initiative to increase pediatric lipid screenings